Thank you for being interested in Investing into QURES GROUP LTD
We are a new start-up company that has technology ready to present to various commercial markets around the world, with answers to some of the biggest problems the planet faces.
Despite the safety and efficacy of OSCN-, it has never been commercialised. There are reasons for this. So, the task I set myself was to overcome the perceived weaknesses and develop formulations and techniques to make OSCN- available to the world. Now that I have achieved my objectives, I am ready to launch the technology to the world.
We seek investors and funds into QURES GROUP LTD. QURES will take on the responsibility to strengthen the knowledge and competence of and about HYPOTHIOCYANITE.
QURES GROUP LTD will finalise the acquisition of Technology and IP relating to HYPOTHIOCYANITE. The first step, is to transfer ownership and control of this IP to Qures Academy. The Academy will have the responsibility to protect and enhance the competence of the IP., Quickly we will start clinical work to verify the safety of the molecule and then human clinical trials against one or more conditions. Whilst numerous academic papers have shown these already, we anticipate that regulators will be looking for evidence created using more modern techniques and standards. Some of this work is already contracted and underway and the first of several animal and human clinical trials will happen very soon, after the Safety status is confirmed.
The acknowledgement of the safety to humans of the technology will make our introduction to all other application and licensees so much easier.
All the technology and IP will be owned by QURES GROUP LTD, through the role of THE QURES ACADEMY
We will earn income from selling licences (big and small) around the world followed by royalties, also big and small, from the successes of the Licensees. Licensees to come from interested, competent and capable parties involved both geographically, commercially and experienced in the application of the technology. We will always have an involvement in any activities/IP based on or utilising our technology to ensure it is protected and enhanced and to enable us to widen our licencing of the technology and enhance value from our existing licensees.
The extent of direct or indirect marketing and sales will be reviewed by independent consultants to determine, assess and compare the relative values of each possible method so as to assist us to identify how we promote the technology to the many different applications and opportunities.
HEALTH will be our initial target market and we intend to retain that licence in our wholly owned subsidiary, UBIQ MEDICINES LTD, as we anticipate that industrial sector to be the largest. As we develop UBIQ MEDICINES, we can seek/consider investment into UBIQ from interested parties.
We see enormous benefits for users of the QURES Technology.
Examples, for the health industry and users, are:
These attributes and cost savings will be of enormous interest to Hospitals, Insurance companies and Governments, plus employers will be able to reduce lost working days by their employees.
1.
Overcome Antibiotic Resistance (ABR and AMR).
2.
Reduce time in hospital for recovery from infections.
3.
Faster delivery of an effective treatment without having to wait for diagnosis
4.
Shorten the period away from work for employees on the 3-4 occasions each year that URTI infections leave them unable to work.
5.
Eventually have the products regulated and allowed for OTC availability.
For Medicine the licence will be retained within QURES, under a new subsidiary company named UBIQ MEDICINES Ltd, into which we will take separate investors, and this we expect will become the largest Licensee of the QURES technology. Because the technology and availability of HYPOTHIOCYANITE is NEW, it is our intention to establish THE QURES ACADEMY to ensure full and correct knowledge and understanding is available to our Licensees and their clients.
You will be asked to complete CDA that ensure you restrict using any confidential details, that we share with you, exclusively to evaluate your investment in QURES GROUP LTD.